共 50 条
- [1] Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeINVESTIGATIONAL NEW DRUGS, 2005, 23 (04) : 357 - 361Chang, SMWen, PCloughesy, TGreenberg, HSchiff, DConrad, CFink, KRobins, HIDe Angelis, LRaizer, JHess, KAldape, KLamborn, KRKuhn, JDancey, JPrados, MD
- [2] Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeInvestigational New Drugs, 2005, 23 : 357 - 361Susan M. ChangPatrick WenTimothy CloughesyHarry GreenbergDavid SchiffCharles ConradKaren FinkH. Ian RobinsLisa De AngelisJeffrey RaizerKenneth HessKen AldapeKathleen R. LambornJohn KuhnJanet DanceyMichael D. Prados
- [3] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group studyJOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5294 - 5304Galanis, EBuckner, JCMaurer, MJKreisberg, JLBallman, KBoni, JPeralba, JMJenkins, RBDakhil, SRMorton, RFJaeckle, KAScheithauer, BWDancey, JHidalgo, MWalsh, DJ
- [4] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patientsJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Sarkaria, J. N.Galanis, E.Wu, W.Giannini, C.Jaeckle, K. A.Doyle, L.Uhm, J.Brown, P.Dietz, A. B.Buckner, J.
- [5] N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis.JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 115S - 115SGalanis, EBuckner, JCMaurer, MJHidalgo, MKreisberg, JIPeralba, JJenkins, RBWalsh, DJ
- [6] Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious RisksCLINICAL CANCER RESEARCH, 2010, 16 (22) : 5573 - 5580Sarkaria, Jann N.Galanis, EvaWu, WentingDietz, Allan B.Kaufmann, Timothy J.Gustafson, Michael P.Brown, Paul D.Uhm, Joon H.Rao, Ravi D.Doyle, LaurenceGiannini, CaterinaJaeckle, Kurt A.Buckner, Jan C.
- [7] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516Sathornsumetee, SithVredenburgh, JamesRich, JeremyDesjardins, AnnickQuinn, JenniferBota, DanielaGoli, KrishnaMathe, AlyssaGururangan, SridharanFriedman, AllanFriedman, HenryReardon, David
- [8] Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572NEURO-ONCOLOGY, 2007, 9 (04) : 518 - 518Schiff, DavidSarkaria, JannDecker, PaulBuckner, JanGalanis, EvanthiaDancey, JanetGiannini, CaterinaBrown, PaulWiesenfeld, MartinJaeckle, Kurt
- [9] N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Galanis, E.Jaeckle, K. A.Maurer, M. J.Reid, J. M.Ames, M. M.Giannini, C.Hardwick, J. S.Moore, D. F., Jr.Zwiebel, J. A.Buckner, J. C.
- [10] CCI-779 in metastatic melanoma - A phase II trial of the California Cancer ConsortiumCANCER, 2005, 104 (05) : 1045 - 1048Margolin, KLongmate, JBaratta, TSynold, TChristensen, SWeber, JGajewski, TQuirt, IDoroshow, JH